Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: Nested case-control study

BMJ (Online)

Volumn 343, Issue 7823, 2011, Pages

  Antoniou, Tony ^a,b   Gomes, Tara ^a,c   Mamdani, Muhammad M ^a,c,d,e   Yao, Zhan ^c   Hellings, Chelsea ^c   Garg, Amit X ^c,f   Weir, Matthew A ^f   Juurlink, David N ^a,c,g  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e KING SAUD UNIVERSITY   (Saudi Arabia)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g Sunnybrook Health Sciences Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; COTRIMOXAZOLE; NITROFURANTOIN; NORFLOXACIN; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST; URINARY TRACT ANTIINFECTIVE AGENT;

AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GERIATRIC PATIENT; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; URINARY TRACT INFECTION; CANADA; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG INTERACTION; RISK; STATISTICAL MODEL; STATISTICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-INFECTIVE AGENTS, URINARY; CASE-CONTROL STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERKALEMIA; LOGISTIC MODELS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NITROFURANTOIN; NORFLOXACIN; ODDS RATIO; ONTARIO; PATIENT ADMISSION; RISK; SPIRONOLACTONE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 83255174632     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d5228     Document Type: Article

References (28)

1. Rocha R, Williams GH. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002;62:723-31. (Pubitemid 34494018)
2. Schrier RW, Masoumi A, Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure and metabolic syndrome. Clin J Am Soc Nephrol 2010;5:1132-40.
3. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001;19:353-61. (Pubitemid 32195369)
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
5. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51. (Pubitemid 39025171)
6. Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 2005;112:39-47. (Pubitemid 40962567)
7. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41:211-4. (Pubitemid 36092186)
8. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297-303. (Pubitemid 39092680)
9. Cruz CS, Cruz AA, Marcílio de Souza CA. Hyperkalemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003;18:1814-9. (Pubitemid 37098553)
10. Eiam-ong S, Kurtzman NA, Sabatini S. Studies on the mechanism of trimethoprim-induced hyperkalemia. Kidney Int 1996;49:1372-8. (Pubitemid 26166410)
11. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993;119:296-301. (Pubitemid 23319887)
12. Perazella MA. Trimethoprim-induced hyperkalemia: clinical data, mechanism, prevention and management. Drug Saf 2000;22:227-36. (Pubitemid 30157583)
13. Marinella MA. Severe hyperkalemia associated with trimethoprim- sulfamethoxazole and spironolactone. Infect Dis Clin Pract 1997;6:257.
14. Martin J, Mourton S, Nicholls G. Severe hyperkalemia with prescription of potassium-retaining agents in an elderly patient. N Z Med J 2003;116:U542.
15. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512-6. (Pubitemid 41103345)
16. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003;289:1652-8. (Pubitemid 37430270)
17. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-61.
18. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751-6. (Pubitemid 38698377)
19. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984;40:63-75.
20. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007;26:734-53. (Pubitemid 46206593)
21. Appel GB, Garvey G, Silva F, Francke E, Neu HC, Weissman J. Acute interstitial nephritis due to amoxicillin therapy. Nephron 1981;27:313-5. (Pubitemid 11072578)
22. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program. J Am Coll Cardiol 2007;50:1959-66. (Pubitemid 350046342)
23. Ponce SP, Jennings AE, Madias NE, Harrington JT. Drug-induced hyperkalemia. Medicine (Baltimore) 1985;64:357-70. (Pubitemid 16197701)
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
25. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64. (Pubitemid 33000813)
26. Hanley JA. A heuristic approach to the formulas for population attributable fraction. J Epidemiol Community Health 2001;55:508-14. (Pubitemid 32591907)
27. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health 1998;17:15-9.
28. Jager LP, De Graaf GJ, Widjaja-Greefkes HCA. Differential effects of nitrofurans on the production/release of steroid hormones by porcine adrenocortical cells in vitro. Eur J Pharmacol 1997;331:325-31. (Pubitemid 27331466)